Page 4 - Pharma Stocks
Biocon shares gain 2% after USFDA inspection at Bengaluru facility; details
The inspection covered various aspects of operations including drug substance manufacturing units, analytical quality control laboratories, microbiology laboratories, and warehouses
 "Biocon shares gain 2% after USFDA inspection at Bengaluru facility; details")
Pharma stock up 37% in 6 mths; Nuvama initiates with 'Buy', eyes 29% gains
According to Nuvama analysts Shrikant Akolkar, Aashita Jain and Gaurav Lakhotia, the company is positioned for robust growth over the medium-term, driven by capacity expansion and product additions.
Lupin share price rises 3% as USFDA okays schizophrenia drug; details
Drugmaker Lupin said it has received the USFDA's approval for Risperidone for extended-release injectable suspension
 "Lupin share price rises 3% as USFDA okays schizophrenia drug; details")
Anlon Healthcare makes flat D-street debut, lists at ₹92 on NSE SME
Post-listing, the Anlon Healthcare stock was trading at ₹91.5, up 0.55 per cent from the listing price on the BSE
 "Anlon Healthcare makes flat D-street debut, lists at ₹92 on NSE SME")
Dr Agarwal's Health Care, Eye Hospital shares tumble up to 17%; here's why
Dr Agarwal's Eye Hospital shares fell 17.7 per cent, while Dr Agarwal's Health Care slid 6.83 per cent on the merger announcement
 "Dr Agarwal's Health Care, Eye Hospital shares tumble up to 17%; here's why")
Sun Pharma slips 5% in 2 days, nears 52-wk low; why drug stock trades weak?
Thus far in August 2025, Sun Pharma has underperformed the market by falling 8 per cent, as compared to a 1 per cent decline in the BSE Sensex
 "Sun Pharma slips 5% in 2 days, nears 52-wk low; why drug stock trades weak?")
SMS Pharmaceuticals shares zoom 10% on clean USFDA inspection report
SMS Pharmaceuticals shares rose 10 per cent after it received an Establishment Inspection Report with a No Action Indicated from the USFDA
 "SMS Pharmaceuticals shares zoom 10% on clean USFDA inspection report")
Concord Biotech shares jump 6 per cent; here's what is fueling the gains
The upward movement in the pharmaceutical company's stock price followed an announcement regarding the company's Limbasi API facility
 "Concord Biotech shares jump 6 per cent; here's what is fueling the gains")
Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here
The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem in the UK, had received marketing authorisation for its products
 "Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here")
Shilpa Medicare share jumps 4% on 1:1 bonus issue; check record date here
Shilpa Medicare shares rose after the company announced a 1:1 bonus issue, with the Board approving the proposal in its meeting on August 13, 2025.
Pfizer share price up 3% on rolling out this vaccine; key details inside
Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.
 "Pfizer share price up 3% on rolling out this vaccine; key details inside")
Sai Life Sciences shares surge 11% in 2 days on strong Q1 earnings
The rally in the share price of Sai Life Sciences comes after the company swung back to report a profit of ₹60 crore in Q1FY26
 "Sai Life Sciences shares surge 11% in 2 days on strong Q1 earnings")
Divi's Labs falls 4% after Q1 miss, analysts trim estimates; check details
Divi's Laboratories reported a 14 per cent year-on-year jump in revenue at ₹2,410 crore in Q1FY26, compared to ₹2,118 crore in the year-ago period
 "Divi's Labs falls 4% after Q1 miss, analysts trim estimates; check details")
Alembic Pharma dips 3% post Q1 results; MOFSL retains Neutral, here's why
Alembic Pharma fell around 3.5 per cent to hit an intraday low of ₹913 on the NSE, after the company reported its June 2025 quarter results
 "Alembic Pharma dips 3% post Q1 results; MOFSL retains Neutral, here's why")
Gland Pharma shares jump 6% post Q1 show; should you buy, sell or hold?
The pharma company's profit after tax (PAT) for the quarter ended June 30, 2025, stood at ₹215 crore, up 50 per cent from ₹143 crore reported in the corresponding quarter of the previous fiscal year.
 "Gland Pharma shares jump 6% post Q1 show; should you buy, sell or hold?")
Aurobindo Pharma stock falls 2% after Q1 results; check key numbers here
Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter last year
 "Aurobindo Pharma stock falls 2% after Q1 results; check key numbers here")
Tariff worries, Sun Pharma Q1 miss: Why are pharma stocks falling today?
Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US
Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show
Indoco Remedies announced that it has received a Certificate of EU GMP Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant II.
 "Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show")
Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook
Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.
 "Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook")
Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY
Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025
 "Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY")